Confirm HumeCare+ Currently Serves Your State Prescription medication available only after consultation and approval by a licensed healthcare provider, if clinically appropriate
Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist
46.Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial
Talk to your client manager today and well help you find the right health plan for your company.
GLP-1 Bridge is a workaround, since it operates outside the Part D benefit, runs on CMSs demonstration authority, and expires on December 31, 2027
A 2026 narrative review in Clinical Obesity by Urbina and colleagues, which pooled six studies covering 480,825 adults, found that more than 60% of GLP-1 users consumed below estimated requirements for calcium and iron, and that average vitamin D intake landed at just 20% of recommendations (PubMed: 41549912)
